RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of IKT
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Volatile ride for Inhibikase Therapeutics, Inc. stock price on Thursday moving between $2.08 and $2.44
(Updated on Mar 28, 2024)

Sell candidate since Mar 11, 2024 Loss -11.11% PDF

The Inhibikase Therapeutics, Inc. stock price fell by -6.09% on the last day (Thursday, 28th Mar 2024) from $2.30 to $2.16. During the last trading day the stock fluctuated 17.54% from a day low at $2.08 to a day high of $2.44. The price has been going up and down for this period, and there has been a 1.41% gain for the last 2 weeks. Volume has increased on the last day by 83 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 97 thousand shares were bought and sold for approximately $210.05 thousand.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.87 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 19.98% during the next 3 months and, with a 90% probability hold a price between $2.25 and $4.35 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

IKT Signals & Forecast

There are few to no technical positive signals at the moment. The Inhibikase Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $2.21 and $2.29. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, January 29, 2024, and so far it has fallen -32.71%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Inhibikase Therapeutics, Inc. gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".

Support, Risk & Stop-loss for Inhibikase Therapeutics, Inc. stock

Inhibikase Therapeutics, Inc. finds support from accumulated volume at $2.15 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.365 between high and low, or 17.54%. For the last week, the stock has had daily average volatility of 8.13%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (IKT) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect Inhibikase Therapeutics, Inc. to open at $2.23, and during the day (based on 14 day Average True Range), to move between $1.94 and $2.38, which gives a possible trading interval of +/-$0.217 (+/-10.05%) up or down from last closing price. If Inhibikase Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 20.09% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $2.15 (0.46%) than the resistance at $2.46 (13.89%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Inhibikase Therapeutics, Inc. stock A Buy?

The Inhibikase Therapeutics, Inc. stock holds several negative signals and despite the positive trend, we believe Inhibikase Therapeutics, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -6.207 Strong Sell Candidate Downgraded

Predicted Opening Price for Inhibikase Therapeutics, Inc. of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$2.23 ( 3.16%) $2.16

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for IKT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.59 20.05 %
R2 2.45 13.60 %
R1 2.37 9.61 %
Current price: 2.16
Support S1 2.09 -3.29 %
S2 2.00 -7.28 %
S3 1.86 -13.73 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.55 18.06 %
R2 2.47 14.35 %
R1 2.46 13.89 %
Current price 2.16
Support S1 2.15 -0.463%
S2 1.76 -18.52%
S3 1.74 -19.44%

FAQ

What is the symbol for Inhibikase Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Inhibikase Therapeutics, Inc. is IKT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Inhibikase Therapeutics, Inc. Stock?
The Inhibikase Therapeutics, Inc. stock holds several negative signals and despite the positive trend, we believe Inhibikase Therapeutics, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

How to buy Inhibikase Therapeutics, Inc. Stock?
Inhibikase Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Inhibikase Therapeutics, Inc. Stock.

What's the current price of Inhibikase Therapeutics, Inc. Stock?
As of the end of day on the 2024-03-28, the price of an Inhibikase Therapeutics, Inc. (IKT) share was $2.16.

What is the 52-week high and low for Inhibikase Therapeutics, Inc. Stock?
The 52-week high for Inhibikase Therapeutics, Inc. Stock is $3.82 and the 52-week low is $0.490.

What is the market capitalization of Inhibikase Therapeutics, Inc. Stock?
As of the 2024-03-28, the market capitalization of Inhibikase Therapeutics, Inc. is 13.362M.

When is the next earnings date for Inhibikase Therapeutics, Inc.?
The upcoming earnings date for Inhibikase Therapeutics, Inc. is Mar 29, 2024.
Click to get the best stock tips daily for free!

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const... IKT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT